title: Open-label pilot study on vitamin D₃ supplementation for antipsychotic-associated metabolic anomalies.
abstract: Previous studies have linked vitamin D deficiency to hypertension, dyslipidemia, diabetes mellitus, and cardiovascular disease. The aim of this study was to investigate the short-term effects of vitamin D₃ supplementation on weight and glucose and lipid metabolism in antipsychotic-treated patients. A total of 19 schizophrenic or schizoaffective patients (BMI>27 kg/m²) taking atypical antipsychotics were recruited and dispensed a 2000 IU daily dose of vitamin D₃. On comparing baseline with week 8 (study end) results, we found a statistically significant increase in vitamin D₃ and total vitamin D levels but no statistically significant changes in weight, glucose, or lipids measurements. Patients whose vitamin D₃ level at week 8 was 30 ng/ml or more achieved a significantly greater decrease in total cholesterol levels compared with those whose week 8 vitamin D₃ measurement was less than 30 ng/ml. These results suggest that a randomized trial with a longer follow-up period would be helpful in further evaluating the effects of vitamin D₃ on weight, lipid metabolism, and on components of metabolic syndrome in antipsychotic-treated patients.
authors.affiliation: Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA.
authors.forename: Neelam
authors.initials: N
authors.lastname: Thakurathi
authors.forename: Shannon
authors.initials: S
authors.lastname: Stock
authors.forename: Claire E
authors.initials: CE
authors.lastname: Oppenheim
authors.forename: Christina P C
authors.initials: CP
authors.lastname: Borba
authors.forename: Brenda
authors.initials: B
authors.lastname: Vincenzi
authors.forename: Larry J
authors.initials: LJ
authors.lastname: Seidman
authors.forename: William S
authors.initials: WS
authors.lastname: Stone
authors.forename: David C
authors.initials: DC
authors.lastname: Henderson
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015992:Body Mass Index; D002762:Cholecalciferol / Q000097:blood / Q000627:therapeutic use*; D019587:Dietary Supplements; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008404:Massachusetts / Q000453:epidemiology; D024821:Metabolic Syndrome / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D008875:Middle Aged; D050177:Overweight / Q000150:complications / Q000453:epidemiology; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D012307:Risk Factors; D012559:Schizophrenia / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D014808:Vitamin D Deficiency / Q000150:complications / Q000178:diet therapy* / Q000503:physiopathology
chemical_list: D014150:Antipsychotic Agents; D002762:Cholecalciferol